0.09%QQQQ 50.01 0.08%MSFT 29.99 
1.51%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
EXTON, Pa. (AP) - Adolor Corp. said Friday that the Food and Drug Administration won't be making a decision on approval of the company's Entereg drug for post-surgery bowel blockage by Saturday, the scheduled action date.
The biopharmaceutical company said the FDA did not provide a specific date, but expects to issue the action letter shortly.
Adolor, with partner GlaxoSmithKline PLC, is seeking marketing approval of Entereg to help speed upper and lower gastrointestinal recovery following partial large or small bowel resection surgery.
Eritrea is considering five more applications for exploration licences, and will make its decision within the year.
A Swiss pilot strapped on a jet-powered wing and leaped from a plane Wednesday f...
The One Laptop Per Child project is about to find out whether Microsoft Corp., a...
|
Professional Website Design For Corporate - Get a Free Quote Today
Find the most up to date research from leading investment firms to make the most informed investing decisions
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
0.05
